Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database.
Vassilakopoulos TP, Piperidou A, Hadjiharissi E, Panteliadou AK, Panitsas F, Vassilopoulos I, Variamis E, Boutsis D, Michail M, Papageorgiou S, Tsourouflis G, Dimou M, Karakatsanis S, Kalpadakis C, Stavroyianni N, Katodritou E, Kotsopoulou M, Kotsianidis I, Verigou E, Hatzimichael E, Leonidopoulou T, Xanthopoulos V, Panayiotidis P, Konstantopoulos K, Dimopoulos MA, Karmiris T, Batsis I, Papaioannou M, Pangalis GA, Angelopoulou MK. Vassilakopoulos TP, et al. Among authors: hatzimichael e. Leuk Res. 2021 Jan;100:106479. doi: 10.1016/j.leukres.2020.106479. Epub 2020 Nov 16. Leuk Res. 2021. PMID: 33285316 No abstract available.
Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.
Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: hatzimichael e. Eur J Haematol. 2012 Jul;89(1):10-5. doi: 10.1111/j.1600-0609.2012.01784.x. Eur J Haematol. 2012. PMID: 22469521
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniatis A, Terpos E. Katodritou E, et al. Among authors: hatzimichael e. Ann Hematol. 2014 Jan;93(1):129-39. doi: 10.1007/s00277-013-1841-y. Epub 2013 Jul 28. Ann Hematol. 2014. PMID: 23892921
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA; Greek Myeloma Study Group. Kastritis E, et al. Among authors: hatzimichael e. Leukemia. 2014 Oct;28(10):2075-9. doi: 10.1038/leu.2014.110. Epub 2014 Mar 18. Leukemia. 2014. PMID: 24637336
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group. Zagouri F, et al. Among authors: hatzimichael e. Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26. Eur J Haematol. 2017. PMID: 28675766
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Papageorgiou SG, et al. Among authors: hatzimichael e. Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16. Am J Hematol. 2018. PMID: 29659040 Free article.
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Katodritou E, et al. Among authors: hatzimichael e. Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Ann Hematol. 2018. PMID: 29756171 Free PMC article.
Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M. Tsirigotis P, et al. Among authors: hatzimichael e. Hematol Oncol. 2018 Oct;36(4):645-650. doi: 10.1002/hon.2521. Epub 2018 Jun 8. Hematol Oncol. 2018. PMID: 29882363
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Katodritou E, et al. Among authors: hatzimichael e. Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8. Ann Hematol. 2018. PMID: 29943159 Free PMC article.
Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Papageorgiou SG, et al. Among authors: hatzimichael e. Leuk Res. 2018 Aug;71:55-59. doi: 10.1016/j.leukres.2018.07.004. Epub 2018 Jul 7. Leuk Res. 2018. PMID: 30007218 No abstract available.
131 results